Author: McKeigue, P. M.; McAllister, D.; Robertson, C.; Hutchinson, S. J.; McGurnaghan, S.; Stockton, D.; Colhoun, H. M.
Title: Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study Cord-id: bz38m3vl Document date: 2021_9_16
ID: bz38m3vl
Snippet: Objectives - To determine whether COVID-19 efficacy varies with clinical risk category and to investigate risk factors for severe COVID-19 in those who have received two doses of vaccine. Design - Matched case-control study (REACT-SCOT). Setting - Population of Scotland from 1 December 2020 to 19 August 2021. Main outcome measure - Severe COVID-19, defined as cases with entry to critical care or fatal outcome. Results - Efficacy against severe COVID-19 of two doses of vaccine was 93% (95 percent
Document: Objectives - To determine whether COVID-19 efficacy varies with clinical risk category and to investigate risk factors for severe COVID-19 in those who have received two doses of vaccine. Design - Matched case-control study (REACT-SCOT). Setting - Population of Scotland from 1 December 2020 to 19 August 2021. Main outcome measure - Severe COVID-19, defined as cases with entry to critical care or fatal outcome. Results - Efficacy against severe COVID-19 of two doses of vaccine was 93% (95 percent CI 90% to 95%) in those without designated risk conditions, 89% (95 percent CI 85% to 92%) in those with moderate risk conditions, but only 66% (95 percent CI 52% to 76%) in those designated as clinically extremely vulnerable (CEV) and eligible for shielding. Of the 330 cases of severe COVID-19 in double-vaccinated individuals, 47% had moderate risk conditions and 41% were CEV. In the double-vaccinated CEV group, the rate ratio for severe disease (with no risk condition as reference category) was highest in solid organ transplants at 98 (95% CI 29 to 332) but even in this subgroup the absolute risk of severe COVID-19 was low (14 cases in 16079 person-months of follow-up). Conclusions - Two doses of vaccine protect against severe COVID-19 in CEV individuals but the residual risk in double-vaccinated individuals remains far higher in those who are CEV than in those who are not. These results suggest that any policy of offering booster doses to doubly-vaccinated individuals should focus initially on the clinically vulnerable, and lay a basis for determining eligibility for passive immunization to protect those at highest risk.
Search related documents:
Co phrase search for related documents- absolute risk and logistic regression model: 1, 2, 3, 4, 5
- absolute risk and low efficacy: 1
- absolute risk reduction and low efficacy: 1
- logistic regression model and low efficacy: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date